CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures.
A tetramethylpyrazine releasing hydrogel can potentiate CAR-T cell therapy against triple negative breast cancer by reprogramming tumor vasculatures.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
实体瘤的不规则血管系统已被证明是限制其应答CAR-T(CAR-T)细胞疗法的关键因素,因为其与缺氧及其他生物屏障密切相关。
在此,我们开发了一种由聚乙二醇二甲基丙烯酸酯(PEGDMA)和氯化亚铁(FeCl2)组成的可注射水凝胶,该水凝胶可响应内源性过氧化氢(H2O2),实现中药提取物川芎嗪(TMP)在瘤内的持续释放。选择TMP是因为其能有效激活血管内皮细胞中血管内皮生长因子(VEGF)的表达以及内皮型一氧化氮合酶/一氧化氮(eNOS/NO)轴。当TMP被固定于基于PEGDMA的水凝胶中并置于肿瘤内后,TMP可通过同时促进血管生成和扩张肿瘤血管来重塑肿瘤血管系统,从而在两种携带人三阴性乳腺癌(TNBC)的小鼠异种移植瘤中减轻肿瘤缺氧。结果,TMP固定治疗通过促进肿瘤浸润、存活和效应功能,增强了静脉注射表达表皮生长因子受体的CAR-T(HER1-CAR-T)细胞对两种TNBC肿瘤异种移植瘤的肿瘤抑制效果。
本研究强调了一种简洁而有效的方法,即通过简单地重塑肿瘤血管系统来增强CAR-T 细胞对靶向实体瘤的治疗效力。
Irregular vasculature of solid tumors has proven to be a pivotal factor restricting their response to chimeric antigen receptor-T (CAR-T) cell therapy because it is tightly associated with hypoxia and other biological barriers.
Herein, an injectable hydrogel composed of poly (ethylene glycol) dimethacrylate (PEGDMA) and ferrous chloride (FeCl 2 ) responding to endogenous hydrogen peroxides (H 2 O 2 ) is developed to enable sustained intratumoral release of Chinese herbal extracts tetramethylpyrazine (TMP). TMP is selected due to its potency in activating vascular endothelial growth factor (VEGF) expression and the endothelial nitric oxide synthase/nitric oxide (eNOS/NO) axis inside vascular endothelial cells.
Upon being fixed inside tumors with the PEGDMA based hydrogel, TMP can remodel tumor vasculature by simultaneously promoting angiogenesis and dilating tumor vasculature and thus attenuate tumor hypoxia in two murine xenografts bearing human triple negative breast cancer (TNBC).
Resultantly, treatment with TMP fixation potentiates the tumor suppression effect of intravenously injected epidermal growth factor receptor expressing CAR-T (HER1-CAR-T) cells toward two TNBC tumor xenografts by promoting their tumor infiltration, survival, and effector function.
This study highlights a concise yet effective approach to reinforce the therapeutic potency of CAR-T cells towards targeted solid tumors by simply remodeling tumor vasculature.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。